PDC and anemia: The three PHD inhibitors were selected because one of them has been used in a clinical trial of anemia (BIQ/FG2216) (34), one has been profiled in some detail for selectivity and potency (IOX2) (35, 36), and another (BNS) has a substantially different heteroaromatic structure (37).